Lidocaine inhalation - Corus Pharma
Alternative Names: Corus 1030Latest Information Update: 20 Jan 2022
At a glance
- Originator Mayo Clinic
- Developer Corus Pharma
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 Aug 2006 Corus Pharma has been acquired by Gilead Sciences
- 14 Mar 2006 Discontinued - Phase-II for Asthma in Germany (Inhalation)
- 14 Mar 2006 Discontinued - Phase-II for Asthma in Poland (Inhalation)